Rating History for Genmab A/S (GMAB) by Morgan Stanley
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 10/20/2026 | Sean Laaman | New Coverage | Equalweight (N/A) |
42.00 (N/A) |
37.00 (43.79) |
18.35% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 10/20/2026 | Sean Laaman | New Coverage | Equalweight (N/A) |
42.00 (N/A) |
37.00 (43.79) |
18.35% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||